%0 Journal Article
%T Impact of first-line infliximab on the pharmacokinetics of
second-line vedolizumab in inflammatory bowel diseases
%A Ann Gils
%A Bram Verstockt
%A Claire Liefferinckx
%A Denis Franchimont
%A Severine Vermeire
%A Sophie Tops
%A Wouter Van Moerkercke
%J Archive of "United European Gastroenterology Journal".
%D 2019
%R 10.1177/2050640619841538
%K Induction
%K inflammatory bowel disease
%K infliximab
%K pharmacokinetics
%K trough level
%K vedolizumab
%K wash-out
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6620879/